A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
220actual
Sites
14
Countries
Germany, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-24 | actual | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Intervention
- Drug: TNB-383B
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose-limiting toxicities (DLT)
measured Day 21
Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
measured Up to 3 Years
Maximum Observed Plasma Concentration of TNB-383B (Cmax)
measured Week 12
Time to Cmax of TNB-383B (Tmax)
measured Week 12
Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUClast)
measured Week 12
Clearance (CL) of TNB-383B
measured Week 12
Terminal Phase Elimination Rate Constant (Beta) of TNB-383B
measured Week 12
Terminal Half-Life (t1/2) of TNB-383B
measured Week 12
Number of Participants with of Anti-drug Antibody (ADA)
measured Up to Month 48
Publications
- PMID 36029527 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed